Last updated: February 27, 2026
What Is the Drug Identified by NDC 70677-1239?
NDC 70677-1239 is a marketed pharmaceutical product. Based on publicly available data, this NDC corresponds to Apretude (cabotegravir extended-release injectable suspension), developed by ViiV Healthcare. It is an injectable for pre-exposure prophylaxis (PrEP) against HIV.
How Is the Market for Apretude Positioned?
Regulatory Status and Approvals
- Approved by the U.S. Food and Drug Administration (FDA) in December 2021.
- Approved under priority review for HIV PrEP.
- Marketed in the U.S., with limited or no initial approval in other jurisdictions.
Market Size and Demand Drivers
- HIV Prevention market is valued at approximately $1.2 billion globally (2019).
- U.S. PrEP market is estimated at $1.1 billion, with nearly 800,000 individuals on PrEP as of 2022.
- Apretude aims to displace daily oral Truvada (tenofovir/emtricitabine) as preferred PrEP due to its bi-monthly injection schedule.
- Potential to increase the PrEP market penetration by appealing to populations with adherence issues.
Competitive Landscape
| Product Name |
Formulation |
Market Share |
Key Advantages |
Cost Point |
| Truvada (Gilead) |
Oral pill |
~70% |
Established efficacy, insurance coverage |
~$2,000/month (rebates vary) |
| Descovy (Gilead) |
Oral pill |
~20% |
Fewer renal/toxicities compared to Truvada |
~$2,000/month |
| Apretude (ViiV) |
Injectable, two doses |
<10% in early phase |
Improved adherence, longer dosing interval |
Estimated ~$3,500 per injection |
Market Penetration Strategies
- Focus on high-risk populations, including men who have sex with men (MSM) and transgender women.
- Collaborate with healthcare systems for patient adherence programs.
- Insurance coverage expansion for injections similar to oral PrEP.
Price Trends and Projections
Current Pricing Landscape
- Apretude is priced at approximately $3,500 per injection, with an initial two-dose regimen.
- The total treatment plan costs approximately $7,000, including a first dose and a follow-up after one month.
Historical Price Trends (Comparable Drugs)
- Oral PrEP (Truvada): prices have ranged from $1,600 to $2,500 per month, with rebates and generic options lowering effective costs.
- Injectable therapies in infectious disease markets (e.g., long-acting antipsychotics) have prices between $1,200 to $4,000 per dose.
Projected Price Movements
| Year |
Projected Price per Dose |
Drivers |
Comments |
| 2023 |
$3,500 |
Initial market entry, limited competition |
|
| 2024 |
$3,200 - $3,500 |
Negotiations with insurers, increasing competition among injectables |
Potential price reductions as volume increases |
| 2025 |
$2,800 - $3,200 |
Patent protection, increased patient volume, formulary coverage |
Entry of biosimilars unlikely in short-term |
Price Sensitivity and Market Dynamics
- Will depend on insurance coverage policies, patient acceptance, and provider adoption.
- Price reductions are expected as more competitors and generics enter the market.
Revenue Outlook and Market Share Projections
| Year |
Estimated Market Penetration |
Total Revenue (USD billions) |
Remarks |
| 2022 |
5% |
~$0.06 |
Early adoption phase, limited coverage |
| 2023 |
12% |
~$0.15 |
Expanded coverage, increased awareness |
| 2024 |
25% |
~$0.32 |
Significant market penetration, price stabilization |
| 2025 |
35% |
~$0.44 |
Broader acceptance and insurance support |
Risks and Opportunities
Risks
- Slow market adoption due to provider familiarity with oral PrEP.
- Premium pricing may limit access among low-income populations.
- Competition from upcoming long-acting therapies or biosimilars.
Opportunities
- Growing awareness of PrEP benefits could spur adoption.
- Long-acting injectable regime potentially reduces adherence barriers.
- Expansion into global markets with unmet needs.
Key Takeaways
- NDC 70677-1239 (Apretude) holds a niche in the HIV PrEP market with premium pricing.
- The market is positioned for growth driven by adherence advantages and expanding indications.
- Price projections suggest stabilization around $2,800 to $3,200 per dose in 2024-2025.
- Revenue growth opportunities depend on insurance coverage, provider education, and competitive dynamics.
FAQs
Q1: When is the next price review for Apretude?
Pricing typically remains stable for 12-24 months post-launch unless significant market or policy changes occur.
Q2: What factors influence reimbursement for this drug?
Coverage depends on formulary decisions, negotiated rebates, and patient assistance programs.
Q3: Are biosimilars expected to enter the market?
Biosimilar development for injectable HIV therapies is not imminent, but biosimilars for the active ingredient could impact pricing long-term.
Q4: How does Apretude compare cost-wise to oral PrEP over five years?
Initial injections cost about $7,000; oral PrEP over five years costs approximately $120,000 at $2,000/month, making injectable slightly more expensive upfront but potentially more cost-effective through adherence.
Q5: What is the market potential outside the U.S.?
Global HIV populations could present significant opportunities, but approval processes, pricing, and reimbursement structures vary.
References
- Gilead Sciences. (2021). Truvada and Descovy Prescribing Information.
- ViiV Healthcare. (2021). FDA approves Apretude (cabotegravir) for HIV prevention.
- IQVIA. (2022). HIV Pre-exposure Prophylaxis Market Data.
- Centers for Disease Control and Prevention (CDC). (2022). HIV Surveillance Report.
- Statista. (2022). Global HIV/AIDS Market Analysis.
